Please login to the form below

Not currently logged in
Email:
Password:

Orilissa

This page shows the latest Orilissa news and features for those working in and with pharma, biotech and healthcare.

Myovant preps US filing for relugolix in prostate cancer

Myovant preps US filing for relugolix in prostate cancer

Myovant is in a head-to-head battle with AbbVie and its rival GnRH inhibitor  Orilissa (elagolix) in endometriosis-related pain and uterine fibroids, but has a clear run at the ... Orilissa has been approved in endometriosis and filed for uterine

Latest news

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics